Pat Gray has spent 35 years in the biotechnology industry, focusing on drug discovery for critical diseases. He has a passion for working in small companies with aggressive timelines—Genentech, ICOS, Macrogenics, Nura and Accelerator were all less than 60 employees when he joined.
Dr. Gray’s career accomplishments include the first cloning and characterization of Hepatitis B surface antigen, Interferon-gamma, multiple Interferon-alpha genes, Lymphotoxin (TNF-beta), Bactericidal Permeability Increasing Protein, LPS-Binding Protein, Platelet Activating Factor Acetylhydrolase, CCR5 (subsequently shown to be the HIV co-receptor), Macrophage Derived Chemokine, and PI3K p110-delta. These discoveries led to numerous clinical trials, several approved human pharmaceuticals, and characterization of targets for therapeutic monoclonal antibodies and small molecules.
In addition to his scientific accomplishments, Dr. Gray previously held senior scientific management positions, including Vice President, Chief Scientific Officer, and CEO. Dr. Gray received his Ph.D. in chemistry from the University of Colorado and his B.S. in biology from the University of Oregon. He is currently an affiliate professor at the University of Washington.
Focus: Life Science, Therapeutics